Alzinova (ALZ.ST) Stock Analysis & AI Equity Report
Alzinova (ALZ.ST) overview
Alzinova (ALZ.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Alzinova reported revenue of SEK 0.0m and operating profit of SEK -20.4m; the year-end share price was 3.46 SEK and market capitalisation was SEK 231m. Alzinova is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Alzinova's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Alzinova
Alzinova AB is a Swedish clinical-stage biopharmaceutical company focused on Alzheimer’s disease. It develops disease-modifying therapies based on its proprietary AβCC peptide technology, including the therapeutic vaccine ALZ-101 in clinical development and the antibody ALZ-201 in preclinical development. The company’s work centers on targeting toxic amyloid-β oligomers.
Generate the Alzinova report
Alzinova is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Alzinova and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.